Cushing’s syndrome is a condition which is due to prolonged exposure of the body tissue to excess cortisol (glucocorticoid hormone).
Laboratory tests and radiological findings confirm diagnosis and determine the actual cause of Cushing's syndrome.
Endogenous adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome has adrenal hypersecretion due to adrenal adenoma, adrenal carcinoma, micronodular hyperplasia, and macronodular hyperplasia.
Exogenous ACTH-independent Cushing's syndrome has adrenal hypersecretion due to iatrogenic causes (eg drug-induced, corticosteroid use).
The use of cabergoline as bridge treatment in Cushing’s disease patients who have undergone radiotherapy does not appear to affect initial remission but is associated with increased recurrence following initial remission, a study reports.
Use of long-acting pasireotide in the treatment of Cushing’s disease (CD) appears to be effective and safe, yielding sustained biochemical and clinical improvements, with a safety profile that is favourable and consistent with that reported during the first year of therapy, according to data from the open-label extension phase of a phase III study.
Treatment with the oral 11β-hydroxylase inhibitor osilodrostat continues to maintain a normalized mean urinary free cortisol (mUFC) in patients with Cushing’s Disease (CD) in a phase III trial presented at ENDO 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Endocrinology - Malaysia digital copy today!
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.